Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study.
10.4093/dmj.2012.36.5.364
- Author:
Juyoung SHIN
1
;
Jin Sun CHANG
;
Hun Sung KIM
;
Sun Hee KO
;
Bong Yun CHA
;
Ho Young SON
;
Kun Ho YOON
;
Jae Hyoung CHO
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. drhopper@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Diabetes mellitus, type 2;
Exenatide;
Glucagon-like peptide 1;
Treatment outcome
- MeSH:
Blood Glucose;
Body Weight;
Cohort Studies;
Diabetes Mellitus, Type 2;
Follow-Up Studies;
Glucagon-Like Peptide 1;
Hemoglobins;
Humans;
Hypoglycemic Agents;
Peptides;
Retrospective Studies;
Treatment Outcome;
Venoms;
Weight Loss
- From:Diabetes & Metabolism Journal
2012;36(5):364-370
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: While many studies have shown the good efficacy and safety of exenatide in patients with diabetes, limited information is available about exenatide in clinical practice in Korean populations. Therefore, this retrospective cohort study was designed to analyze the effects of exenatide on blood glucose level and body weight in Korean patients with type 2 diabetes mellitus. METHODS: We reviewed the records of the patients with diabetes who visited Seoul St. Mary's Hospital and for whom exenatide was prescribed from June 2009 to October 2011. After excluding subjects based on their race/ethnicity, medical history, whether or not they changed more than 2 kinds of oral hypoglycemic agents with exenatide treatment, loss to follow-up, or whether they stopped exenatide therapy within 6 months, a total of 52 subjects were included in the final analysis. RESULTS: The mean glycated hemoglobin (HbA1c) level and weight remarkably decreased from 8.5+/-1.7% to 6.7+/-1.0% (P<0.001) and from 82.3+/-15.8 kg to 78.6+/-16.3 kg (P<0.001), respectively. The multiple regression analysis indicated that the reduction in HbA1c level was significantly associated with a shorter duration of diabetes, a higher baseline HbA1c level, and greater weight reduction, whereas weight loss had no significant correlation with other factors. No severe adverse events were observed. CONCLUSION: These results suggest that a 6-month exenatide injection therapy significantly improved patients' HbA1c levels and body weights without causing serious adverse effects in Korean patients with type 2 diabetes.
